SCHEMBL31710568

SCHEMBL31710568

Cc1ccccc1-c1cc(=O)oc2cc(N(C)Cc3ccccc3)ccc12

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ IGLV6-57 P01721 3/20 0.52
▸ KCNA3 P22001 1/20 0.49
▸ MEN1 O00255 4/20 0.47
▸ KMT2A Q03164 4/20 0.47
▸ SLC16A3 O15427 1/20 0.47
▸ SLC16A1 P53985 1/20 0.47
▸ HSD17B3 P37058 1/20 0.47
▸ ACHE P22303 1/20 0.46
▸ ALDH1A1 P00352 3/20 0.46
▸ HPGD P15428 3/20 0.46
▸ HSD17B10 Q99714 3/20 0.46
▸ NPSR1 Q6W5P4 2/20 0.46
▸ KDM4E B2RXH2 2/20 0.46
▸ LMNA P02545 1/20 0.46
▸ GLA P06280 2/20 0.44
▸ CASP1 P29466 2/20 0.44
▸ CASP7 P55210 2/20 0.44
▸ CYP3A4 P08684 1/20 0.44
▸ MAPK1 P28482 1/20 0.44
▸ ATM Q13315 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30228494 0.87 IGLV6-57 (0.46) IGLV6-57KCNA3MEN1KMT2ASLC16A3
SCHEMBL30227938 0.85 IGLV6-57 (0.51) IGLV6-57KCNA3MEN1KMT2AHSD17B3
SCHEMBL30228373 0.84 KCNA3 (0.46) IGLV6-57KCNA3MEN1KMT2AHSD17B3
SCHEMBL30228077 0.84 KCNA3 (0.56) IGLV6-57KCNA3MEN1KMT2AHSD17B3
SCHEMBL30228207 0.84 IGLV6-57 (0.47) IGLV6-57KCNA3MEN1KMT2AHSD17B3
SCHEMBL30228360 0.84 IGLV6-57 (0.47) IGLV6-57KCNA3HSD17B3ALDH1A1HPGD
SCHEMBL30228335 0.83 IGLV6-57 (0.49) IGLV6-57KCNA3MEN1KMT2AHSD17B3
SCHEMBL30228039 0.83 IGLV6-57 (0.46) IGLV6-57KCNA3MEN1KMT2AHSD17B3
SCHEMBL30228402 0.83 IGLV6-57 (0.46) IGLV6-57KCNA3MEN1KMT2AHSD17B3
SCHEMBL30228123 0.83 IGLV6-57 (0.51) IGLV6-57KCNA3MEN1KMT2AHSD17B3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250326732-A1 CHROMEN-2-ONE MODULATORS OF POLRMT PRETZEL THERAPEUTICS, INC. (US) 2025-10-23 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250326732-A1 CHROMEN-2-ONE MODULATORS OF POLRMT POLRMT, TFAM, POLM IGLV6-57 4814/4885KCNA3 4258/4885MEN1 3371/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback